CERE - Cerevel Therapeutics Holdings, Inc. Stock Price, Fair Value and News

44.62USD+0.22 (+0.50%)Market Closed

Market Summary

USD44.62+0.22

Market Closed

0.50%

CERE Alerts

1 major insider sales recently.

CERE Stock Price

View Fullscreen

CERE RSI Chart

CERE Valuation

Market Cap

8.1B

Price/Earnings (Trailing)

-17.65

Price/Sales (Trailing)

34.2K

EV/EBITDA

-18.37

Price/Free Cashflow

-21.92

CERE Price/Sales (Trailing)

CERE Profitability

EBT Margin

-205300.45%

Return on Equity

-81.58%

Return on Assets

-40.85%

Free Cashflow Yield

-4.56%

CERE Fundamentals

CERE Revenue

Revenue (TTM)

224.0K

CERE Earnings

Earnings (TTM)

-460.5M

Earnings Growth (Yr)

-26.49%

Earnings Growth (Qtr)

0.56%

Breaking Down CERE Revenue

Last 7 days

4.0%

Last 30 days

14.5%

Last 90 days

5.1%

Trailing 12 Months

48.6%

How does CERE drawdown profile look like?

CERE Financial Health

Current Ratio

10.22

Debt/Equity

0.6

Debt/Cashflow

-1.09

CERE Investor Care

Shares Dilution (1Y)

16.17%

Diluted EPS (TTM)

-2.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	0	0	0
2020	1.3M	1.0M	489.6K	224.0K
2019	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Ronald C. Renaud Jr., M.B.A., MBA
WEBSITE	cerevel.com
INDUSTRY	Biotechnology
EMPLOYEES	322

Cerevel Therapeutics Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Cerevel Therapeutics Holdings, Inc.? What does CERE stand for in stocks?

CERE is the stock ticker symbol of Cerevel Therapeutics Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerevel Therapeutics Holdings, Inc. (CERE)?

As of Fri Jul 26 2024, market cap of Cerevel Therapeutics Holdings, Inc. is 8.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERE stock?

You can check CERE's fair value in chart for subscribers.

Is Cerevel Therapeutics Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether CERE is over valued or under valued. Whether Cerevel Therapeutics Holdings, Inc. is cheap or expensive depends on the assumptions which impact Cerevel Therapeutics Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERE.

What is Cerevel Therapeutics Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CERE's PE ratio (Price to Earnings) is -17.65 and Price to Sales (PS) ratio is 34.21 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERE PE ratio will change depending on the future growth rate expectations of investors.